Real-world treatment patterns and survival in stage IV non-small-cell lung cancer in Canada
| Autor: | Soo Jin Seung, R. Walton, M. Hurry, William K. Evans |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Male medicine.medical_specialty Canada Lung Neoplasms medicine.medical_treatment 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Gefitinib stage iv disease Internal medicine Carcinoma Non-Small-Cell Lung Pragmatic Clinical Trials as Topic medicine Humans 030212 general & internal medicine Longitudinal Studies Stage (cooking) Lung cancer real-world evidence Aged Neoplasm Staging Retrospective Studies Cisplatin Chemotherapy business.industry Middle Aged medicine.disease Survival Analysis Gemcitabine Carboplatin respiratory tract diseases chemistry 030220 oncology & carcinogenesis Cohort Female business medicine.drug |
| Zdroj: | Current Oncology Volume 27 Issue 4 Pages 6049-367 |
| ISSN: | 1718-7729 |
| DOI: | 10.3747/co.27.6049 |
| Popis: | Almost half of all patients with non-small-cell lung cancer (nsclc) present with stage iv disease. The objective of the present study was to characterize treatment patterns and survival outcomes in patients with advanced nsclc. We conducted a longitudinal population-level study in patients diagnosed with stage iv nsclc in Ontario between 1 April 2010 and 31 March 2015, with follow-up to 31 March 2017 for overall survival and treatment sequence. Patients were stratified as nonsquamous or squamous histology. A sub-analysis was conducted for patients with nonsquamous histology who received targeted therapies, on the assumption that their tumours were EGFR mutation&ndash positive (EGFRm+). Treatment patterns were determined, and survival was calculated from date of diagnosis to death or censoring. Of 24,729 nsclc cases identified, stage iv disease was diagnosed in 49.2%, histology was nonsquamous in 10,103, and EGFRm+ was assumed in 508. Median patient age ranged from 69 to 72 years for the three cohorts. For patients with nonsquamous histology, palliative radiotherapy was the most frequently used first-line treatment (44.4%), followed by no treatment (26.7%) and chemotherapy (14.9%). In the EGFRm+ cohort, 75.6% received gefitinib as first- or second-line therapy, and almost half (47.4%) the 473 patients with squamous histology treated with first-line chemotherapy received cisplatin or carboplatin with gemcitabine. Median overall survival in the nonsquamous and squamous cohorts was 4.9 and 4.6 months respectively it was 17.6 months for patients who were EGFRm+. Survival of patients with stage iv nsclc remains poor, with the exception of patients who are EGFRm+. Only 14.9% of patients received first-line chemotherapy the mainstay of treatment was palliative radiotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|